Syndax Pharmaceuticals Inc.
400 Totten Pond Road
Suite 110
Waltham
Massachusetts
02451
United States
Tel: 781-419-1400
Fax: 781-419-1420
Website: http://www.syndax.com/
Email: info@syndax.com
183 articles with Syndax Pharmaceuticals Inc.
-
Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021
8/2/2021
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it will release its second quarter 2021 financial results on Monday, August 9, after the close of the U.S. financial markets.
-
SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias
6/28/2021
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias harboring a mixed lineage leukemia rearranged or nucleophosmin mutation.
-
The U.S. FDA granted Fast Track Designation to three biopharma companies for the treatment of LGMD, episodic bleeding and leukemia.
-
Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference
6/3/2021
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021
-
Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit
5/13/2021
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, 2021
-
Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update
5/11/2021
Today announced two of the prior responders from ongoing Phase 1 portion of AUGMENT-101 trial of SNDX-5613 achieved full count recovery bringing CR/CRh rate up to 23%
-
Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
5/4/2021
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.
-
Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias
4/20/2021
48% overall response rate in patients with MLLr or NPM1c; 67% of responders achieved minimal residual disease-negative status
-
Syndax Pharmaceuticals announced its treatment for mixed-lineage leukemia demonstrated robust clinical activity in a Phase I/II study.
-
Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias
4/15/2021
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias on Tuesday, April 20,
-
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis
4/8/2021
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab
-
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease
3/31/2021
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab,
-
Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update
3/8/2021
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2020.
-
Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021
3/1/2021
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter and year-end 2020 financial results on Monday, March 8 , after the close of the U.S. financial market
-
Syndax Announces Participation at Two Upcoming Investor Conferences - Feb 24, 2021
2/24/2021
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate in two upcoming virtual investor conferences
-
Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index
12/18/2020
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI), effective prior to market open on Monday, December 21, 2020.
-
Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
12/11/2020
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public offering of 6,250,000 shares of its common stock, which includes the exercise in
-
Syndax Announces Pricing of Public Offering of Common Stock
12/9/2020
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced today the pricing of an underwritten public offering of 5,434,783 shares of its common stock at a price to the public of $23.00 per share
-
Syndax Announces Proposed Public Offering of Common Stock - Dec 07, 2020
12/7/2020
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
-
ASH 2020: CRISPR and Vertex's Potential Cure for Sickle Cell Disease and More Glimmers of Hope
12/7/2020
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5, and there were numerous presentations, abstracts and posters. Here’s a look at some of the stories out of the first day.